Oncogenic Raf-1 Disrupts Epithelial Tight Junctions via Downregulation of Occludin by Li, Danxi & Mrsny, Randall J.
 
ã
 
 The Rockefeller University Press, 0021-9525/2000/02/791/10 $5.00
The Journal of Cell Biology, Volume 148, Number 4, February 21, 2000 791–800
http://www.jcb.org 791
 
Oncogenic Raf-1 Disrupts Epithelial Tight Junctions via Downregulation 
of Occludin
 
Danxi Li and Randall J. Mrsny
 
Department of Pharmaceutical Research and Development, Genentech Inc., South San Francisco, California 94080
 
Abstract. 
 
Occludin is an integral membrane protein of 
the epithelial cell tight junction (TJ). Its potential role 
in coordinating structural and functional events of TJ 
formation has been suggested recently. Using a rat sali-
vary gland epithelial cell line (Pa-4) as a model system, 
we have demonstrated that occludin not only is a criti-
cal component of functional TJs but also controls the 
phenotypic changes associated with epithelium onco-
genesis. Transfection of an oncogenic Raf-1 into Pa-4 
cells resulted in a complete loss of TJ function and the 
acquisition of a stratiﬁed phenotype that lacked cell–
cell contact growth control. The expression of occludin 
and claudin-1 was downregulated, and the distribution 
patterns of ZO-1 and E-cadherin were altered. Intro-
duction of the human occludin gene into Raf-1–acti-
vated Pa-4 cells resulted in reacquisition of a mono-
layer phenotype and the formation of functionally 
intact TJs. In addition, the presence of exogenous oc-
cludin protein led to a recovery in claudin-1 protein 
 
level, relocation of the zonula occludens 1 protein (ZO-1) 
to the TJ, and redistribution of E-cadherin to the lateral 
membrane. Furthermore, the expression of occludin in-
 
hibited anchorage-independent growth of Raf-1–acti-
vated Pa-4 cells in soft agarose. Thus, occludin may
act as a pivotal signaling molecule in oncogenic Raf-
1–induced disruption of TJs, and regulates phenotypic 
changes associated with epithelial cell transformation.
Key words: occludin • Raf-MEK-ERK signaling • 
tight junction • claudin-1 • epithelium transformation
 
Introduction
 
Epithelia exhibit specialized structures involved in cell–
cell contacts known as tight junctions (TJs)
 
1
 
 and adherens
junctions (AJs). AJ complexes are involved in maintain-
ing cell–cell adhesions between adjacent epithelial cells,
whereas TJ structures provide the barrier to uncontrolled
paracellular permeability. The positioning of these junc-
tions is coordinated and stabilized through associations
with a continuous band of bundled actin filaments known
as an adhesion belt (Madara, 1998). Occludin is a trans-
membrane protein located at TJ complexes (Saitou et al.,
1997) and appears to be involved in the tight coupling be-
tween adjacent epithelial cells (Wong and Gumbiner,
1997; Lacaz-Vieira et al., 1999). Interactions of occludin
with several other components of the TJ have been pro-
posed (Fanning et al., 1999). In particular, an association
with intracellular protein zonula occludens 1 (ZO-1) (Fu-
ruse et al., 1994) has led to the possibility that occludin may
act to organize the annular ring of actin present in the cy-
tosol at the neck of epithelial cells (Madara, 1998). Many
studies suggest that occludin is involved in the barrier and
fence functions of the TJs: overexpression of occludin in
MDCK cells increases the number of TJ strands and their
transepithelial electrical resistance (TEER) (McCarthy et
al., 1996); the COOH terminus of occludin is required for
the correct assembly of TJ barrier function (Chen et al.,
1997); small synthetic peptides homologous to the external
loops of occludin impair TJ resealing (Wong, 1997; Lacaz-
Vieira et al., 1999); and a dominant mutant of occludin can
disrupt TJ structure and function (Bamforth et al., 1999).
However, there is also evidence indicating that occludin is
not the only integral membrane protein involved in estab-
lishing the paracellular barrier of the TJ. When occludin
was overexpressed in mouse L fibroblasts, only short and
poorly developed TJ strand–like structures were formed
(Furuse et al., 1998a). In primary cultured rat hepatocytes,
disruption of circumferential actin filament caused disap-
pearance of occludin from the cell borders without distinct
changes in TJ strands (Kojima et al., 1999). Most directly,
occludin knockout embryonic stem cells formed well-
developed TJ structures (Saitou et al., 1998). These find-
ings have led to the recent identification of claudins, a
family of transmembrane proteins located at epithelial TJs
(Furuse et al., 1998b). Although the exact physiological
function of occludin in TJs remains unresolved, it is likely
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that claudins and occludin can interact in a collaborating
way in order to achieve the full function of TJs as a para-
cellular barrier and transmembrane fence.
Loss of TJ and AJ structures is frequently observed in
epithelium-derived cancers (Quinonez and Simon, 1988).
E-cadherin at AJ complexes signals through interactions
involving 
 
a
 
-, 
 
b
 
-, and 
 
g
 
-catenins (Weiss et al., 1998) and
loss of functional coupling through E-cadherin has been
shown to induce a transformed phenotype in epithelial
cells (Takeichi, 1993). Although epithelial-derived cancers
appear to be lacking both AJ and TJ complexes (Quino-
nez and Simon, 1988), a role for functional coupling
through TJ structures similar to that observed through AJ
structures has not been described. It is possible that anti-
neoplastic signaling through TJ structures is similar to that
observed for AJ structures. This is supported by the find-
ing that several tumor-promoting agents can induce TJ
disruption (Soler et al., 1993), and that neoplastic progres-
sion can be correlated with an increase in paracellular per-
meability across epithelia, suggesting a loss of TJ function
(Mullin et al., 1997). If signaling through cell–cell contacts
at AJ and TJ structures is important for growth and differ-
entiation events in epithelial cells, then similar mecha-
nisms may control the activity of these two systems.
Sequence mutations that result in a constitutively active
state of the small GTP-binding protein Ras are commonly
associated with epithelium oncogenesis (Yuspa and Poir-
ier, 1988). Also, the cell activation characteristics of 
 
ras
 
mutations make it an important component in the cascade
of genetic alterations described for cancers derived from
epithelial cell sheets (Vogelstein et al., 1988). Thus, Ras
and the intracellular pathways driven by Ras would be
prime candidates for possible regulatory function if TJ sig-
naling was a component of epithelial cell transformation.
Activated Ras stimulates multiple intracellular signaling
pathways (Marshall, 1996). In particular, Raf-1 is consid-
ered to be a primary and central downstream effector of
Ras (Marshall, 1996). A well-established signaling path-
way activated by Raf-1 involves sequential phosphoryla-
tion and activation of mitogen-activated protein kinase
(MEK) and extracellular-regulated kinase (ERK) kinases
(Cobb et al., 1994). Activated ERK kinases regulate a
variety of cellular processes, including proliferation, dif-
ferentiation, and transformation (Cobb et al., 1994). We
manipulated the activity of Raf-1 in Pa-4 cells, an immor-
talized rat parotid gland cell line, which grows as a mono-
layer with high TEER on semipermeable filter supports
similar to normal epithelia. Stable transfections of Pa-4
cells were carried out with an oncogenic Raf-1, 
 
D
 
Raf-1:
ER, which was constructed by fusing the kinase domain of
Raf-1 with the hormone-binding domain of estrogen re-
ceptor (Samuels et al., 1993). We have shown that a consti-
tutively active Raf-1 induces the transition of Pa-4 cells
from a high-resistance monolayer to a low-resistance mul-
tilayer phenotype characteristic of oncogenic conversion.
These modified cells demonstrate a redistribution of the
actin cytoskeleton along with a downregulation of occlu-
din expression. In addition, introduction of an exogenous
occludin gene into Raf-1–activated Pa-4 cells resulted in
reacquisition of normal epithelial monolayer phenotype
and functionally intact TJs. Furthermore, the expression
of exogenous occludin appeared to stabilize and coordi-
 
nate membrane localization of other junctional proteins
in Raf-1–activated Pa-4 cells, and the presence of occlu-
din also inhibited anchorage-independent growth of Pa-
4
 
D
 
Raf:ER cells. Based on these results, we suggest that
occludin plays a critical role in the disruption of epithelial
TJs induced by oncogenic Raf-1.
 
Materials and Methods
 
Reagents and Antibodies
 
An antibody that specifically recognizes the phosphorylated form of ERK1
and ERK2 was purchased from Santa Cruz Biotechnologies, Inc. Antibod-
ies to occludin, ZO-1, and claudin-1 were purchased from Zymed Laborato-
ries, Inc. An antibody to E-cadherin was from Transduction Laboratories.
PD98059, a selective inhibitor of MEK, was purchased from Calbiochem.
Rhodamine-phalloidin was obtained from Molecular Probes, Inc.
 
Constructs and Plasmids
 
A constitutively active Raf-1 (
 
D
 
Raf-1:ER), comprised of the catalytic do-
main of human Raf-1 fused with the hormone-binding domain of human
estrogen receptor was constructed as described (Samuels et al., 1993). An
active 
 
ras
 
 plasmid, c-Ki-ras2, was kindly provided by Dr. David Goeddel,
Genentech Inc., South San Francisco, CA (Capon et al., 1983). Raf BXB,
a constitutively active form of Raf-1 containing only the catalytic domain
of the kinase, was kindly provided by Dr. Jakob Troppmair, University of
Wurzburg, Wurzburg, Germany (Bruder et al., 1992). An active MEK
mutant, pFC-MEK1, was obtained from Stratagene. Human occludin
cDNA was cloned using a T84 cell library (Stratagene). The probe used in
cloning and Northern blotting was obtained by reverse transcription–
PCR. Human occludin cDNA was then subcloned into pCB6 vector,
which has a cytomegalovirus promotor.
 
Cell Culture, Transfections, and Treatments
 
Pa-4
 
D
 
Raf-1:ER cells were established as described previously by stably
transfecting Pa-4 cells with the 
 
D
 
Raf-1:ER construct (Li et al., 1997). Pa-
4-vec and Pa-4
 
D
 
Raf-1:ER cells were cultured in DMEM/F12 (1:1) medium
supplemented with 2.5% FBS, insulin (5 
 
m
 
g/ml), transferrin (5 
 
m
 
g/ml),
EGF (25 ng/ml), hydrocortisone (1.1 
 
m
 
M), glutamate (5 mM), G418 (600
 
m
 
g/ml), and were maintained in a humidified atmosphere containing 5%
CO
 
2
 
 and 95% air at 35
 
8
 
C. Pa-4
 
D
 
Raf-1:ER-occludin cells were raised by
stably transfecting Pa-4
 
D
 
Raf-1:ER cells with pCB6-occludin and pTK-
Hyg vector (Clontech) for hygromycin selection (100 
 
m
 
g/ml). Charcoal-
stripped serum was used in maintaining Pa-4
 
D
 
Raf-1:ER and Pa-4
 
D
 
Raf-1:
ER-occludin cells to minimize the estrogen level in the culture medium.
Cells grown on semipermeable supports were plated at 10
 
6
 
 cells/cm
 
2
 
 onto
collagen-coated clear polyester membrane of Costar Transwell
 
®
 
 (0.4-
 
m
 
m
pore size, 1-cm
 
2
 
 surface area). The transepithelial resistance of confluent
epithelial sheets was measured after 1 wk in culture with a chopstick Milli-
cell-ERS
 
®
 
 voltmeter (Millipore). Transient transfections were performed
using Lipofectamine Plus™ (Life Technologies, Inc.) and following the
manufacturer’s protocol. Cells were collected and lysed 48 h after the start
of transfection. Treatment of PD98059 in the transient transfection exper-
iments was carried out by adding the inhibitor (20 
 
m
 
M final) 5 h after the
start of transfection. Medium was replaced every 24 h with fresh PD98059.
 
Western and Northern Blottings
 
Western Blotting. 
 
Cell lysates, prepared as Triton X-100–soluble and
–insoluble fractions, were made as described previously (Li et al., 1997).
In brief, cells were lysed in gold lysis buffer (Samuels et al., 1993) contain-
ing 20 mM Tris-HCl, pH 8.0, 137 mM NaCl, 5 mM EDTA, 10% (vol/vol)
glycerol, 1% (vol/vol) Triton X-100, 1 mM PMSF, 1 mM aprotinin, 1 mM leu-
peptin, 1 
 
m
 
M pepstatin A, 1 mM sodium orthovanadate, 1 mM EGTA,
10 mM NaF, 1 mM tetrasodium pyrophosphate, 100 
 
m
 
M 
 
b
 
-glycerophos-
phate at 4
 
8
 
C. Lysates were incubated at 4
 
8
 
C for 10 min, and the insoluble
material was removed by centrifugation at 12,000 
 
g
 
 for 10 min at 4
 
8
 
C. Tri-
ton X-100–insoluble pellets were dissolved in RIPA buffer containing
0.2% SDS. Protein concentrations were determined by Pierce BCA assay.
Equal amounts of protein of cellular lysates (20 
 
m
 
g) were subjected to
SDS-PAGE. After electrophoresis, proteins were electroblotted onto
PVDF membranes (Bio-Rad Laboratories). Membranes were blocked 
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with 5% milk solution for 1 h before incubation with primary antibodies.
HRP-conjugated secondary antibodies and the enhanced chemilumines-
cence detection system (NEN™ Life Science Products, Inc.) were used to
detect bound antibodies. The quantitative analyses of protein levels were
carried out using the NIH Image 1.60/PPC software.
 
Northern Blotting. 
 
Total cellular RNA was prepared using TRIzol™ re-
agent according to the manufacturer’s instructions (Life Technologies).
Denatured samples were size fractionated on a formaldehyde (2.2 M)/aga-
rose (1.5%) gel, blotted onto a ZetaProbe nylon membrane (Bio-Rad
Laboratories) and hybridized with a 
 
32
 
P-labeled DNA probe prepared us-
ing the Ready-To-Go DNA labeling kit (Amersham Pharmacia Biotech).
Northern analysis for claudin-1 message levels was carried out using a
PCR-derived cDNA sequence probe (Furuse et al., 1998). Glyceraldehyde
3-phosphate dehydrogenase mRNA levels were monitored as loading
controls.
 
Microscopy and Confocal Imaging
 
Phase-contrast microscopy of cells on plastic culture dishes was done us-
ing a Nikon Diaphot 300 inverted microscope attached to a Nikon N6006
camera. Cells grown on Transwell
 
®
 
 filters were fixed in 10% normal buff-
ered formalin. Thin sections cut from paraffin-embedded samples were
stained with hematoxylin and eosin and viewed by light microscopy. Char-
acterization of filamentous actin distribution was achieved using cells
fixed in formalin, permeabilized with 0.2% (vol/vol) Triton X-100, and la-
beled with rhodamine-phalloidin as described previously (Phillips and
Tsan, 1988). Immunofluorescence staining of occludin, ZO-1, E-cadherin,
and claudin-1 was carried out on cells fixed in methanol at 
 
2
 
20
 
8
 
C for 10
min. Cells were then analyzed using a Leica TCS SP laser scanning confo-
cal microscope.
 
Measurement of Cloning Efficiency in Soft Agarose
 
Pa-4-vec, Pa-4
 
D
 
Raf-1:ER, and Pa-4
 
D
 
Raf-1:ER-occludin cells were plated
at 10,000 cells per 35-mm culture dish in 1 ml of 0.35% (wt/vol) low melt-
ing temperature (LMT) agarose solution diluted with medium in the ab-
sence or presence of 1 
 
m
 
M estradiol. The dishes were coated with 1 ml of
0.7% (wt/vol) LMT agarose before cell plating, and 1 ml of overlay me-
dium was added after cell plating. The overlay medium was changed every
3 d and fresh estradiol was added. After 15 d, the cells were stained with
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT; 0.05
mg/ml). The stained plates were photographed, and colonies 
 
.
 
0.4 mm in
diameter were counted and analyzed.
 
Results
 
Activated Raf-1 Modulates Epithelial Cell Phenotype 
and Downregulates Occludin Expression
 
Raf-1 is a serine/threonine kinase composed of two regula-
tory and one catalytic domain (Morrison and Cutler,
1997). Deletion of the regulatory domains of Raf-1 results
in a constitutively active form capable of driving MEK-
ERK pathway kinase activities. Pa-4 is an immortalized
epithelial cell line derived from rat parotid gland, which
grows as polarized monosheet in vitro with high transepi-
thelial resistance. Stable transfections of Pa-4 cells were
generated with a constitutively active construct of Raf-1
(Li et al., 1997). The expression of 
 
D
 
Raf-1:ER protein and
activation of the Raf-MEK-ERK kinase pathway in the
stably transfected cells, Pa-4
 
D
 
Raf-1:ER, have been charac-
terized previously (Li et al., 1997). Here, we verified an
increased Raf-1 activity in Pa-4
 
D
 
Raf-1:ER cells by mea-
suring the phosphorylation levels of ERK1 and ERK2
(Fig. 1 A). When grown on plastic, Pa-4
 
D
 
Raf-1:ER cells
displayed significant morphological changes compared
with vector-transfected control cells (Pa-4-vec) (Fig. 1 B),
and had prominent stress fibers instead of pericellular ac-
tin rings (Fig. 1 C). When cultured on semipermeable filter
supports, Pa-4
 
D
 
Raf-1:ER cells lost their ability to form
high-resistance monolayers and acquired a stratified, low-
resistance phenotype (Fig. 1 D). Immunofluorescence
staining of occludin showed normal peripheral distribution
pattern in control cells, but there was only background
staining of occludin in Pa-4
 
D
 
Raf-1:ER cells (Fig. 1 E).
Western analyses revealed that Pa-4-vec cells had high lev-
els of occludin protein in both Triton X-100–soluble and
–insoluble lysates (Fig. 1 F). In the Triton X-100–insoluble
fraction, where cytoskeleton-associated proteins are en-
riched (Wong, 1997), a large percentage of occludin was
hyperphosphorylated and probably represented a func-
tional component of the TJ (Fig. 1 F). By comparison, Pa-
4
 
D
 
Raf-1:ER cells completely lost their expression of oc-
cludin (Fig. 1 F, arrow). Northern analysis demonstrated
that the downregulation of occludin protein in Pa-4
 
D
 
Raf-
1:ER cells correlated with a complete loss of occludin
mRNA (Fig. 1 G).
A recent study on the actions of vascular permeability
factor on endothelial cell function has suggested that the loss
of occludin at cell junctions occurs via the ERK-involved
pathway (Kevil et al., 1998). Also, Ki-Ras activation has
been shown to alter cell–cell contacts in polarized MDCK
cells, inducing them to lose their monolayer phenotype
and grow as multilayers (Schoenenberger et al., 1991). We
examined the possible involvement of the Ras-Raf-MEK-
ERK signaling module in regulating occludin expression.
Pa-4 cells were transiently transfected with either an onco-
genic k-ras (Capon et al., 1983), another active mutant of
 
Raf-1
 
, Raf BXB (Bruder et al., 1992), or a constitutively
active 
 
MEK1
 
, pFC-MEK1. Northern blots revealed de-
creases of 31, 39, and 44% in occludin mRNA levels, re-
spectively (Fig. 2). The partial changes of occludin mRNA
levels observed in this experiment were likely due to the
limitation of transfection efficiency. In addition, downreg-
ulation of occludin expression induced by pFC-MEK1 was
blocked by PD98059 (Fig. 2), a selective inhibitor of ERK
activation (Dudley et al., 1995). In another cell system,
A549, which has high Ras-Raf signaling activity due to an
oncogenic 
 
K-ras
 
 mutation, we observed an upregulation of
occludin by transfecting a dominant negative Raf-1 con-
struct or by treating the cells with PD98059 (Li, D., and R.J.
Mrsny, manuscript in preparation). Taken together, it is
likely that active Raf-1 downregulated occludin expression
in Pa-4 cells through the MEK-ERK signaling pathway.
 
Introduction of Exogenous Occludin into
Pa-4
 
D
 
Raf-1:ER Cells Resulted in Reacquisition of 
Normal Epithelial Phenotype and Functionally
Intact TJs
 
Although we made the observation that occludin was
downregulated in Raf-1–activated cells, this downregula-
tion could be a side effect of Raf-1 activation and have no
relevance to the disruption of epithelial TJs. To directly
assess the potential role of occludin in stabilizing func-
tional epithelial TJs, we introduced an exogenous occludin
gene (human) driven by the cytomegalovirus promoter
into Pa-4
 
D
 
Raf-1:ER cells, which no longer express endog-
enous occludin. A total of eight Pa-4
 
D
 
Raf-1:ER-occludin
cell clones were isolated and analyzed. Data from a repre-
sentative clone, clone No. 2, have been presented for most
studies. Control transfections with pCB6 vector alone did 
The Journal of Cell Biology, Volume 148, 2000 794
 
not yield any clones distinguishable from Pa-4
 
D
 
Raf-1:ER
cells. Occludin-transfected Pa-4
 
D
 
Raf-1:ER cells were veri-
fied to have similar levels of 
 
D
 
Raf-1:ER protein and phos-
phorylated ERK1 and ERK2 compared with Pa-4
 
D
 
Raf-1:
ER cells (Fig. 3 A), indicating that elevated activity of the
Raf-MEK-ERK kinase pathway was maintained. Immuno-
blotting of protein lysates of Pa-4
 
D
 
Raf-1:ER-occludin cells
confirmed the presence of occludin in both Triton X-100–
soluble and –insoluble fractions (Fig. 3 B), and hyperphos-
phorylated occludin in the Triton X-100–insoluble fraction
only (Fig. 3 B, arrow). Immunostaining of Pa-4
 
D
 
Raf-1:
ER-occludin cells verified the normal distribution of oc-
cludin at the periphery of cells (Fig. 3 C). To demonstrate
that the occludin protein detected was exogenous, PCR
primers were designed using unique sequences in the 5
 
9
 
-
 
Figure 1.
 
Comparison of Pa-4-vec (1) and Pa-4
 
D
 
Raf-1:ER (2)
cells based on phenotype and occludin expression. Stable Pa-4
cell clones were selected after transfection with a control vector
or an oncogenic Raf-1, 
 
D
 
Raf-1:ER (Samuels et al., 1993). (A) Ac-
tivation of ERK1 and ERK2 in Pa-4
 
D
 
Raf-1:ER cells. Protein ly-
sates were immunoblotted with an antibody to phosphorylated
ERK1 and ERK2. (B) Pa-4-vec and Pa-4
 
D
 
Raf-1:ER cells grown
on plastic displayed differences in plating phenotype. (C)
Rhodamine-phalloidin labeling of actin showed the loss of
circumferential actin rings and appearance of stress fibers in
Pa-4
 
D
 
Raf-1:ER cells. (D) Pa-4-vec cells grew as epithelium
monosheets on semipermeable supports with high TEER,
whereas Pa-4
 
D
 
Raf-1:ER cells acquired a stratified phenotype
and lost functional TJs. Average TEER values of both cell types
are shown. (E) Immunofluorescence staining (Cy5) of occludin in
Pa-4-vec and Pa-4
 
D
 
Raf-1:ER cells. (F) Western blots with an an-
tibody to occludin. S, Triton X-100–soluble; I, Triton X-100–
insoluble. Arrow indicates hyperphosphorylated occludin. Actin
was used as loading control. (G) Northern blots using a probe de-
rived from human occludin cDNA sequence (Furuse et al., 1993).
Glyceraldehyde 3-phosphate dehydrogenase (G3PDH) mRNA
levels were shown as loading control. Bars, 10 
 
m
 
m.
Figure 2. Activation of the Ras-Raf-MEK-ERK kinase pathway
downregulated the expression of occludin in Pa-4 cells. Pa-4 cells
were transiently transfected with an oncogenic k-ras (Capon et al.,
1983), an active Raf-1 (Raf BXB) (Bruder et al., 1992), or an ac-
tive MEK1 in the absence or presence of 20 mM of PD98059. To-
tal RNA was extracted 48 h after the start of transfection, and
Northern analyses were carried out to assess occludin mRNA
levels. The percent control is the mean 6 SEM from three inde-
pendent experiments, and was calculated relative to the level in
mock-transfected cells. Asterisk indicates P , 0.05 vs. control. 
Li and Mrsny 
 
Regulation of Occludin Expression
 
795
 
untranslated regions of rat and human occludin cDNAs.
Reverse transcription–PCR results revealed that rat occlu-
din mRNA was only present in Pa-4-vec cells, whereas hu-
man occludin mRNA was only detectable in Pa-4
 
D
 
Raf-1:
ER-occludin cells (Fig. 3 D). When cultured on plastic, Pa-
4
 
D
 
Raf-1:ER-occludin cells displayed morphology indistin-
guishable from that of Pa-4-vec cells (Fig. 3 E), and had
similar annular rings of actin (Fig. 3 F). When cultured on
semipermeable filter supports, Pa-4
 
D
 
Raf-1:ER-occludin
cells formed monolayers (Fig. 3 G) with TEER values of
 
z
 
900 
 
V
 
·cm
 
2
 
 (Fig. 3 H), demonstrating the assembly of
functional TJs. It is not surprising that the TEER of Pa-
4
 
D
 
Raf-1:ER-occludin cells did not recover fully to control
levels, because these cells still have elevated Raf-1 activity,
which is likely to affect other components responsible for
the fine-tuning of epithelial TJs. Another possible reason
is that human occludin protein may not work perfectly in a
rat cell line. But our results clearly demonstrated that oc-
cludin played a crucial role in oncogenic Raf-1–induced
disruption of epithelial TJs.
 
Occludin Protein Assists in the Membrane Localization 
of ZO-1 and E-Cadherin in Raf-1–activated Pa-4 Cells
 
To investigate the potential role of occludin in coordinat-
ing other junctional proteins, we examined cellular distri-
bution and expression of ZO-1, a TJ-associated protein,
and E-cadherin, an AJ-associated protein. In Pa-4-vec
cells, ZO-1 colocalized with occludin at the TJs (Fig. 4 A),
whereas E-cadherin localized next to occludin towards the
basolateral side (Fig. 4 B). However, the distribution pat-
terns of ZO-1 and E-cadherin were disrupted in the occlu-
din-absent Pa-4
 
D
 
Raf-1:ER cells. Although ZO-1 protein
was no longer exclusively located at the cell–cell contact
points in Pa-4
 
D
 
Raf-1:ER cells, there was still a substantial
amount of ZO-1 appearing as plaques along the cell bor-
der, suggesting its membrane localization is independent
of occludin expression and functional TJs. Introduction of
exogenous occludin restored the distribution patterns of
these two proteins to those observed in control cells (Fig.
4, A and B). Raf-1 activation did not significantly affect
the overall protein level of ZO-1, but slightly reduced the
ZO-1 level in Triton X-100–insoluble fractions. The level
of Triton X-100–insoluble ZO-1 recovered after introduc-
tion of occludin (Fig. 4 C). This is consistent with our im-
munofluorescence results, where we observed a decrease
in ZO-1 levels at the lateral membrane in Pa-4
 
D
 
Raf-1:ER
cells, and a reconcentration at the TJs in Pa-4
 
D
 
Raf-1:ER-
occludin cells. A similar scenario also occurred for E-cad-
herin distribution, although Raf-1 activation seemed to
have decreased the total protein level of E-cadherin (Fig. 4
C), consistent with other reports that E-cadherin is down-
regulated in transformed epithelial cells (Guilford, 1999).
 
Figure 3.
 
Expression of exogenous occludin induced the forma-
tion of functional epithelial cell TJs in Pa-4
 
D
 
Raf-1:ER cells. (A)
Western blots using antibodies to human estrogen receptor (top),
phosphorylated ERK1 and ERK2 (middle), or actin (bottom).
Lanes 1, 2, and 3 represent Pa-4-vec, Pa-4
 
D
 
Raf-1:ER, Pa-4
 
D
 
Raf-1:
ER-occludin, respectively. Similar results were seen in all
eight Pa-4
 
D
 
Raf-1:ER-occludin clones. (B) Pa-4
 
D
 
Raf-1:ER-
occludin lysates were immunoblotted with an antioccludin anti-
body. S, Triton X-100–soluble; I, Triton X-100–insoluble. Arrow
indicates hyperphosphorylated occludin. (C) Immunofluores-
cence staining (Cy5) showing occludin was concentrated at the
cell borders. (D) Total RNA was isolated from Pa-4-vec (lane 1),
Pa-4
 
D
 
Raf-1:ER (lane 2), and Pa-4
 
D
 
Raf-1:ER-occludin (lane 3)
cells. Reverse transcription–PCR was performed using primer
sets specific for rat occludin, human occludin, or glyceraldehyde
3-phosphate dehydrogenase (G3PDH) (as control). (E) Pa-4
 
D
 
Raf-
1:ER-occludin cells grown on plastic displayed similar phenotype
to that of Pa-4-vec cells. (F) Rhodamine-phalloidin labeling of
actin showed the reappearance of pericellular actin rings in
Pa-4
 
D
 
Raf-1:ER-occludin cells. (G) Pa-4
 
D
 
Raf-1:ER-occludin cells
cultured on semipermeable filters grew as monolayers. (H) For-
mation of functional epithelial TJs in Pa-4
 
D
 
Raf-1:ER-occludin
cells. TEER of Pa-4-vec (square), Pa-4
 
D
 
Raf-1:ER (triangle), and
Pa-4
 
D
 
Raf-1:ER-occludin (circle) cells grown on filters were mea-
sured using a chopstick voltmeter. Data represent the mean 
 
6
 
SEM of six filters from each cell type. Bars,
 
 
 
10 
 
m
 
m. 
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Our observation implies that occludin may play a role in
the localization of these junctional proteins.
 
Occludin Protein Stabilized Claudin-1 Protein in
Raf-1–activated Pa-4 Cells
 
Claudins have been implicated in the structure and func-
tion of TJ strands (Tsukita and Furuse, 1999). So far 16
members of the claudin gene family have been reported.
Claudin-1 was found in TJ strands associated largely with
the P-face in freeze-fractured images (Furuse et al., 1998),
and the amount of P-face TJ strand particles has been
shown to correlate with the tightness of TJs (Wolburg et al.,
1994), suggesting its involvement in tight TJs. Since Pa-4
cells have relatively tight TJs with TEER 
 
.2,000 V·cm2,
we examined claudin-1 as a representative of the claudin
gene family in our system. Unlike occludin, the majority of
claudin-1 protein was Triton X-100–soluble in control Pa-4
cells and only a small percentage was detected in the Tri-
ton X-100–insoluble fraction (Fig. 5 A). This suggests that
claudin-1 may not be as directly associated with the actin
cytoskeleton as occludin. Claudin-1 protein was almost un-
detectable in Pa-4DRaf-1:ER cells, but recovered to the
levels seen in Pa-4-vec cells after the reexpression of oc-
cludin (Fig. 5 A). Although there was a decrease of clau-
din-1 mRNA level in Pa-4DRaf-1:ER cells, surprisingly,
Pa-4DRaf-1:ER-occludin cells showed a level of claudin-1
mRNA comparable to that of Pa-4DRaf-1:ER cells (Fig. 5
B) even with the apparent difference in protein levels. To
further investigate this observation, we examined the pro-
tein levels of occludin and claudin-1 in eight different Pa-
4DRaf-1:ER-occludin cell clones. The levels of occludin
protein varied significantly among the clones (Fig. 5 C).
This is likely due to the location effects of gene insertion
during stable transfection. We observed a general correla-
tion between the protein levels of claudin-1 and those of
occludin in the Pa-4DRaf-1:ER-occludin clones (Fig. 5 C),
but the levels of claudin-1 mRNA among the clones did
not change significantly (Fig. 5 D). Therefore, it seems
possible that claudin-1 protein was stabilized by the pres-
ence of occludin protein in Raf-1–activated Pa-4 cells.
Costaining of claudin-1 and occludin revealed some colo-
calization between these two proteins in Pa-4-vec and Pa-
4DRaf-1:ER-occludin cells (Fig. 5 E). Thus, active Raf-1
can completely downregulate the expression of occludin
(no detectable mRNA or protein) and decrease the ex-
pression of claudin-1, although to a lesser extent compared
with occludin (50% decrease of mRNA, 95% decrease of
protein). It is possible that the loss of claudin-1 protein in
Pa-4DRaf-1:ER cells was due to accelerated protein degra-
dation, implicating a role for occludin in the stabilization
of claudin-1. The mechanism of this stabilization is un-
known, but may result from protein–protein interactions
between occludin and claudin-1 at the TJs. We also no-
ticed that the TEER among the Pa-4DRaf-1:ER-occludin
clones did not correlate with the expression levels of oc-
cludin or claudin-1 (data not shown), suggesting that oc-
cludin and claudins are not the only players in regulating
epithelial TJ function. A delicate balance between clau-
dins and occludin levels and other regulatory components
of TJs might be necessary to achieve the maximum barrier
function.
Occludin Expression Inhibited Clonal Formation of
Pa-4DRaf-1:ER Cells in Soft Agarose
Cancer cells grow aggressively and invasively. In a cell cul-
ture system, this is represented by their ability to grow an-
chorage-independently in soft agarose. Although the basal
activity of DRaf-1:ER fusion kinase was sufficient to dis-
rupt TJ function and suppress occludin expression in Pa-4
cells, the kinase activity of DRaf-1:ER can be further in-
duced in the presence of added estradiol. Further induc-
tion of Raf-1 activity can greatly increase the ability of Pa-
4DRaf-1:ER cells to form colonies in soft agarose plates
(Li et al., 1997). We examined the effect of occludin rein-
troduction on the growth characteristics of Raf-1–acti-
vated Pa-4 cells. We found that expression of occludin in
Figure 4. Subcellular localization and
expression levels of ZO-1 and E-cad-
herin. Cells grown on filters were
fixed and labeled with antibodies for
(A) occludin and ZO-1 (yz single fo-
cal planes), or (B) occludin and E-cad-
herin (yz single focal planes). Oc-
cludin, Cy5 labeled (red); ZO-1 and
E-cadherin, FITC labeled (green).
The lateral membrane staining of oc-
cludin is due to secondary antibody
effects. Bar, 10 mm. (C) Protein im-
munoblots probed with anti–ZO-1,
anti–E-cadherin, or antiactin antibod-
ies. Lanes 1, 2, and 3 represent Pa-4-
vec, Pa-4DRaf-1:ER, Pa-4DRaf-1:
ER-occludin, respectively. S, Triton
X-100–soluble; I, Triton X-100–insol-
uble. Blots shown are representatives
from three independent experiments.Li and Mrsny Regulation of Occludin Expression 797
Pa-4DRaf-1:ER cells significantly decreased their ability to
grow in soft agarose in the absence or presence of estra-
diol (Fig. 6). Thus, there is a possibility that upregulation
of occludin expression could be a potential approach to
treat Raf-1–induced epithelial cancers.
Discussion
Mechanisms that control functional aspects of cell–cell
contacts are not yet fully understood. Events commonly
associated with the oncogenic transformation of epithelial
cells, however, include the loss of cell–cell contacts and the
acquisition of more migratory and invasive phenotypes
(Birchmeier et al., 1993). Deregulation or loss of function
of AJ and gap junction communications has been shown to
occur in epithelial-derived cancers (Bulkholm et al., 1998;
Ruch et al., 1998). However, the impact of TJ function on
oncogenic transformation of epithelial cells has not been
clearly established. Many studies have focused on Rac and
Rho, two small GTPases downstream of Ras, as regulators
of TJ function. Neither Rac nor Rho appears to have a di-
rect effect on expression levels of occludin and ZO-1 (Jou
et al., 1998), although Rho signaling induces posttrans-
lational modification on these two TJ components (Go-
Figure 5. The expression levels of
claudin-1 in Pa-4-vec, Pa-4DRaf-1:ER,
and Pa-4DRaf-1:ER-occludin cells. (A)
Western blotting with an anti–claudin-1
antibody. S, Triton X-100–soluble; I,
Triton X-100–insoluble. Lanes 1, 2,
and 3 represent Pa-4-vec, Pa-4DRaf-1:
ER, and Pa-4DRaf-1:ER-occludin
cells, respectively. (B) Northern blot-
ting with a PCR-derived claudin-1
probe. Lanes 1, 2, and 3 represent Pa-
4-vec, Pa-4DRaf-1:ER, and Pa-4DRaf-
1:ER-occludin cells, respectively. (C)
Protein levels of occludin and claudin-1
in different Pa-4DRaf-1:ER-occludin
clones. Lanes 1–8 represent eight dif-
ferent Pa-4DRaf-1:ER-occludin clones.
The average levels of occludin and
claudin-1 in clone 1 were set at 100,
and the protein levels in other clones
were calculated by comparing with
clone 1 after normalization against ac-
tin. R, correlation coefficient. (D)
Claudin-1 mRNA levels in Pa-4DRaf-
1:ER-occludin clones. Lanes 1–8 rep-
resent eight different Pa-4DRaf-1:
ER-occludin clones. (E) Immunofluo-
rescence staining of occludin and clau-
din-1. Cells grown on filter supports
were fixed and costained with antioc-
cludin (FITC-labeled) and anti–clau-
din-1 (Cy5-labeled) antibodies. Yel-
low indicates colocalization. The
lateral membrane staining of claudin-1
is due to secondary antibody effects.
Data shown are representatives from
at least two independent experiments.
Bar, 10 mm.The Journal of Cell Biology, Volume 148, 2000 798
palakrishnan et al., 1998). Inactivation of Rho function by
ADP ribosylation with C3 exoenzyme from C. botulinum
leads to a disruption of TJ function through a loosening of
the adhesive band of actin in intestinal epithelial cells
(Nusrat et al., 1995). Constitutively active forms of Rho
and Rac can also disrupt TJ function through a disorgani-
zation of occludin, ZO-1, and actin in MDCK cells (Jou et
al., 1998). These studies suggest that these GTPases must
be finely controlled for the normal structure and function
of TJ complexes.
Using the chimeric construct DRaf-1:ER in a rat salivary
epithelial cell system, we have shown that Raf-1 acts as a
signal transducer capable of modulating TJ function. Reg-
ulation of occludin expression by Raf-1 may represent a
previously unappreciated mechanism in epithelial cell
transformation. Although the kinase activity of DRaf-1:
ER can be further increased in the presence of added es-
tradiol, the DRaf-1:ER fusion protein has a high level of
basal activity (Li et al., 1997). This basal activity is suffi-
cient to induce morphology changes, disruption of TJs,
and downregulation of occludin and claudin-1 in Pa-4
cells. That is why most of our studies were carried out in
the absence of added estradiol. We have analyzed each
of the eight Pa-4DRaf-1:ER-occludin clones obtained
through stable transfection. Although these cells showed
different levels of occludin and claudin-1 expression, many
other properties of these clones that we have studied were
similar. For instance, they all maintained high levels of
DRaf-1:ER expression, comparable to that of the Pa-
4DRaf-1:ER cells. When cultured on semipermeable filter
supports, all eight clones grew as monolayers. Immunoflu-
orescence staining also revealed normal distributions of
occludin, claudin-1, ZO-1, and actin in these clones. We
have also examined the potential effects of added estradiol
on Pa-4DRaf-1:ER-occludin cells. Further activation of
DRaf-1:ER by estradiol did not change the monolayer
phenotype or TEER in any of the Pa-4DRaf-1:ER-occlu-
din clones (data not shown), nor did it change the inability
of these cells to grow in soft agarose (Fig. 6). These results
are consistent with our other observations, demonstrating
that the downregulation of occludin is a downstream cellu-
lar event after Raf-1 activation, and reexpression of occlu-
din can reverse some of the phenotypic changes induced
by active Raf-1.
Although the MEK-ERK kinase pathway is likely in-
volved in the Raf-1–controlled occludin expression, the
details of this regulation remain unresolved. Raf-1 signal-
ing may downregulate occludin at the transcription level
or through accelerated protein degradation. In Pa-4DRaf-
1:ER-occludin cells, exogenous (human) occludin protein
did not appear to be degraded, even though these cells
maintained elevated Raf-1 activity. Human occludin pro-
tein is highly homologous to rat occludin. If we assume
that the occludin degradation machinery in rat cells can
recognize human occludin, our data would suggest that the
downregulation of occludin by activated Raf-1 was not
through accelerated protein degradation. In addition, we
have shown that constitutive activation of Raf-1 led to the
complete loss of occludin mRNA in Pa-4 cells, clearly
demonstrating that changes at the message level were in-
volved. Furthermore, in A549 cells, which have an onco-
genic K-ras mutation, inhibition of the Raf-MEK-ERK ki-
Figure 6. Expression of occludin suppressed anchorage-indepen-
dent growth of Pa-4DRaf-1:ER cells in soft agarose. (A) Repre-
sentative photographs of dimethylthiazol-diphenyltetrazolium
bromide (MTT)-stained dishes. Pa-4-vec (panels a and b), Pa-
4DRaf-1:ER (panels c and d), and Pa-4DRaf-1:ER-occludin
(panels e and f) cells were plated at 10,000 cells/35-mm dish in
semisolid media containing 0.35% low melting temperature aga-
rose in the absence (panels a, c, and e) or presence (panels b, d,
and f) of 1 mM estradiol. The cells were stained with 0.05 mg/ml
MTT after 15 d. (B) The average number of colonies obtained
from three 35-mm dishes/group 6 SD is represented graphically.
Colonies  .0.3 mm in diameter were counted. Similar results
were seen in seven of eight Pa-4DRaf-1:ER-occludin clones.Li and Mrsny Regulation of Occludin Expression 799
nase pathway by a dominant negative Raf-1 mutant or by
the MEK inhibitor PD98059 resulted in increased mRNA
level of occludin (Li, D., and R.J. Mrsny, manuscript in
preparation). Although we can not rule out the possibility
that Raf-1 modulates the stability of occludin mRNA, we
think it is more likely that Raf-1 regulates occludin expres-
sion at the transcription level rather than through degra-
dation.
Raf-1 activation appeared to have broad effects on sev-
eral other TJ-associated proteins, including claudin-1 and
ZO-1. ZO-1 is known to directly interact with occludin
(Furuse et al., 1994). A recent study reported that con-
nexin-occludin chimeras containing the ZO-binding do-
main of occludin localized at epithelial cell TJs and nonep-
ithelial cell contacts (Mitic et al., 1999). In fibroblasts, it
has been shown that claudin-1 or claudin-2 recruited oc-
cludin to reconstituted TJ strands (Furuse et al., 1998). We
observed that in occludin-absent Pa-4DRaf-1:ER cells, the
TJ localization of ZO-1 was disrupted and claudin-1 pro-
tein was downregulated. The introduction of exogenous
occludin into these cells led to the reappearance of ZO-1
and claudin-1 proteins in the TJs. Although the mecha-
nisms underlying these changes are unclear, our study sug-
gests that the TJ targeting interaction among these pro-
teins could be bidirectional. The changes of claudin-1 and
ZO-1 in Pa-4DRaf-1:ER cells are likely to have contrib-
uted to the disruption of TJs induced by active Raf-1.
However, the fact that reintroduction of occludin alone re-
sulted in the return of normal epithelial phenotype and es-
tablishment of functional TJs implicates occludin as a
more direct target in the signaling cascade originated from
Raf-1. Expression of occludin seemed able to increase the
protein level of claudin-1, possibly through stabilization,
suggesting a direct interaction between occludin and clau-
dins. The recovery of TEER seen in Pa-4DRaf-1:ER-
occludin cells could be a direct result of the recovery in
claudin-1 protein level, since there is evidence demonstrat-
ing TJ structures in the absence of occludin (Saitou et al.,
1998). Although the individual and combined functions of
occludin and claudins at epithelial TJs are still unclear, we
have clearly demonstrated an essential role for occludin in
the loss of structure and function of the epithelial TJs in
Ras-Raf–driven epithelial transformation.
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